Manufacturing of AYUSH 64 to surge as CCRAS transfers technology to 46 companies

The move of CCRAS will lead to an increase in its production and will also make it easier to meet its demand

November 20, 2021

CCRAS transfers technology of AYUSH 64 drug to 46 companies

The Central Council for Research in Ayurvedic Sciences (CCRAS) has transferred the technology of AYUSH 64 which is an effective drug to treat mild and asymptomatic and mild to moderate cases of COVID-19, to 46 companies.

Earlier only seven companies including IMPCL, the manufacturing unit of the Ministry of AYUSH, had its license, which used it for the treatment of malaria. After being found effective in Corona during the Covid outbreak, 39 new companies have been given fresh licenses with technology transfer.

CCRAS, the premier institution for research in Ayurveda has developed the AYUSH 64 under the Ministry of AYUSH.

During the first wave of COVID-19 in March 2020, some scientific studies found it to be very effective in mild and asymptomatic and mild to moderate infection of COVID-19. It also has properties of fighting viruses, increasing the body’s immunity, and reducing fever helping patients recover quickly.

AYUSH Ministry conducted a clinical trial on the drugs in association with the Council of Scientific and Industrial Research during the first wave of the COVID-19 pandemic. So far, a total of eight clinical trials have been done on the drug wherein AYUSH 64 was administered to 63,000 patients quarantined at home, and it was found beneficial in the trial.

This move of CCRAS will lead to an increase in its production and will also make it easier to meet its demand. To date, no case of side effects for this medicine have been reported, yet experts suggest taking it only after consulting the doctors, the Ministry of Ayush said.

[With Inputs from IANS]
PGurus is now on Telegram. Click here to join our channel and stay updated with all the latest news and views

For all the latest updates, download PGurus App.